US Patent Issued to Novo Nordisk on May 19 for "Treatment of heart failure in human subjects" (German Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,630,822, issued on May 19, was assigned to Novo Nordisk A/S (Bagsvaerd, Denmark).

"Treatment of heart failure in human subjects" was invented by Thomas Thum (Hannover, Germany), Claudia Ulbrich (Hannover, Germany), Wilfried Hauke (Wiesbaden, Germany), Steffen Rump (Sehnde, Germany) and Sandor Batkai (Hannover, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention refers to an oligonucleotide, which is an effective inhibitor of microRNA miR-132 and its use in medicine, particularly in the prevention or treatment of cardiac and/or fibrotic disorders of a human subject."

The patent was filed on June 12, 2020, under Application No. 17...